Insights

Impedimed (ASX:IPD) share price dips following capital raising update

The company announced the results of its capital raise.
The post Impedimed (ASX:IPD) share price dips following capital raising update appeared first on The Motley Fool Australia. –

The Impedimed Limited (ASX: IPD) share price has come out of a trading halt today to backtrack mid-afternoon. This comes after the medical technology company provided an update on its recent equity raise.

At the time of writing, Impedimed shares are swapping hands for 16.5 cents, down 2.94%.

Impedimed completes placement

One catalyst for today’s fall in the Impedimed share price could be investor concerns over an impending share dilution.

According to its release, Impedimed announced it has received firm commitments for its institutional placement to raise $35 million before costs. The company highlighted that it had strong support from existing and new institutional and sophisticated investors.

The offer will see approximately 229.5 million new ordinary shares issued at a price of 15.25 cents apiece. This represents a 10.3% discount to the last closing price of 17 cents on 22 October (before going into a trading halt).

Impedimed will use the proceeds to support an array of strategic initiatives to address growth. In particular, it will allocate the fund to:

Product enhancement of the SOZO II digital health platform, including weight scales and improved electronics for renal and heart failure
Data and software enhancements including corporate account development such as electronic health record integration and heart failure programs
Development and commercialisation of renal failure application, including end stage renal disease clinical trial and US FDA clearance
General working capital to achieve breakeven, including advance inventory purchases to assist in the transition to SOZO II

In addition, Impedimed will launch a non-underwritten share purchase plan (SPP) of $5 million which it will offer to eligible investors. The terms will be the same as the institutional placement.

The SPP closes on 11 November, with the issuance of the new shares set for 18 November.

Management commentary

Impedimed managing director and CEO, Richard Carreon, said:

We are very encouraged by the level of support investors have shown as we look to capitalise on the significant opportunity with the recently released PREVENT Trial results. Following the completion of the capital raising, we are now in a fully funded position to accelerate sales in Oncology, while still investing in our other key focus areas of Renal Failure and Heart Failure.

About the Impedimed share price

Despite today’s falls, Impedimed shares have gained around 90% in the past 12 months. However, the company’s share price is around 15% off its 52-week high of 19 cents reached on 19 October.

Based on valuation grounds, Impedimed presides a market capitalisation of around $247 million, with almost 1.5 billion shares outstanding.

The post Impedimed (ASX:IPD) share price dips following capital raising update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Impedimed right now?

Before you consider Impedimed, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Impedimed wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

What’s going on with the Impedimed (ASX:IPD) share price?

The Impedimed (ASX:IPD) share price is up 10% on trial success

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!